GSK plc (LSE: GSK, NYSE: GSK) opened 2026 with first-quarter turnover of £7.6 billion, up 5 per cent at constant exchange rates and 2 per cent at actual exchange rates, as Specialty Medicines growth more than absorbed weakness in Vaccines and General Medicines. Core operating profit rose 10 per cent at constant exchange rates to £2.65 billion and core earnings per share climbed 9 per cent to 46.5 pence. GSK reaffirmed full-year 2026 guidance of 3 to 5 per cent turnover growth, 7 to 9 per cent core operating profit growth and 7 to 9 per cent core earnings per share growth, alongside its 2031 outlook of more than £40 billion in turnover. GSK shares closed at 2,027.50 pence ahead of the announcement, having outperformed the FTSE All-Share Index by over 26 percentage points across the previous year.
The print confirmed the strategic direction chief executive officer Luke Miels has been pushing since taking the role. Specialty Medicines turnover reached £3.23 billion, up 14 per cent at constant exchange rates, with Oncology rising 28 per cent to £512 million, Respiratory, Immunology and Inflammation up 16 per cent to £890 million, and HIV up 10 per cent to £1.82 billion. Vaccines turnover rose 4 per cent at constant exchange rates to £2.15 billion on a record Shingrix quarter of £1.03 billion. General Medicines fell 6 per cent at constant exchange rates to £2.25 billion, with Trelegy broadly stable at £646 million but the wider respiratory portfolio under generic and pricing pressure.
How does GSK’s Specialty Medicines engine reshape the long-term earnings profile against Vaccines decline and General Medicines erosion?
The 14 per cent constant exchange rate increase in Specialty Medicines is the single most important number in this release because it determines whether the GSK 2031 outlook of more than £40 billion in turnover remains credible. Specialty Medicines now contributes 42 per cent of group turnover, with the segment delivering core operating leverage through richer product mix, US channel pricing favourability and higher royalty income.
Within HIV, the long-acting injectables Apretude and Cabenuva together drove 73 per cent of HIV growth in the quarter. Apretude rose 44 per cent at constant exchange rates to £120 million and Cabenuva rose 31 per cent at constant exchange rates to £368 million, with Cabenuva alone contributing more than half of total HIV growth. The dolutegravir franchise, anchored by Dovato at £666 million and Tivicay at £311 million, still produced 4 per cent constant exchange rate growth, but the strategic priority is the transition to long-acting regimens before dolutegravir loss of exclusivity later in the decade. The pivotal CUATRO study readout in 2027 for the every-four-months HIV treatment regimen, and the EXTEND data due in the second half of 2026 for every-four-months pre-exposure prophylaxis, are the two clinical events that will determine whether GSK can extend the long-acting injectable franchise into a second generation of dosing intervals before generic dolutegravir arrives.
Oncology momentum is similarly concentrated. Jemperli rose 40 per cent at constant exchange rates to £232 million on US uptake in primary advanced or recurrent endometrial cancer following label expansion. Ojjaara and Omjjara rose 34 per cent to £144 million on continued European and International launches in myelofibrosis. Blenrep added £23 million following the National Medical Products Administration approval in China for second-line plus relapsed or refractory multiple myeloma based on the DREAMM-7 trial, with more than 15 regulatory approvals globally for the asset in the second-line setting. Zejula was the negative print at minus 11 per cent at constant exchange rates following June 2025 US Food and Drug Administration labelling restrictions and prior authorisation requirements that compressed US volume.
The vulnerability is concentration. Specialty Medicines growth is carried by a narrow group of products including Dovato, Cabenuva, Apretude, Nucala, Benlysta, Jemperli and Ojjaara, and any setback in one materially compresses the group growth rate. GSK has tried to address this through tuck-in acquisitions and pipeline filings, but the operational reality remains that fewer than ten assets are doing most of the work in the highest-growth segment.
Why did GSK file bepirovirsen across four major regions in a single quarter and what does the regulatory package signal about the broader pipeline thesis?
GSK’s most consequential pipeline event in the quarter was the simultaneous regulatory acceptance of bepirovirsen filings in the United States, European Union, China and Japan, with the US Food and Drug Administration setting a Prescription Drug User Fee Act decision goal date of 26 October 2026 under priority review. Bepirovirsen received US Food and Drug Administration Breakthrough Therapy Designation in the quarter, adding to the SENKU designation in Japan and Breakthrough Therapy Designation in China.
If approved on its current label, bepirovirsen would become the first finite six-month therapeutic option for chronic hepatitis B, a market that includes roughly 250 million chronically infected people globally and which has lacked durable treatment options for decades. The B-Well 1 and B-Well 2 phase III trials demonstrated functional cure rates significantly higher than standard of care, with functional cure defined as undetectable hepatitis B virus DNA and surface antigen for at least 24 weeks after stopping all treatment. Detailed clinical data will be presented at the European Association for the Study of the Liver congress in the second quarter, which will be the first opportunity for hepatology specialists to scrutinise durability, safety and patient selection criteria.
Beyond bepirovirsen, the quarter delivered regulatory approval for Exdensur in the European Union and China for severe asthma with eosinophilic phenotype and chronic rhinosinusitis with nasal polyps, expanding the depemokimab franchise into the two largest ex-US territories. Nucala received European Union approval in chronic obstructive pulmonary disorder, and Lynavoy was approved in the United States for cholestatic pruritus in primary biliary cholangitis, although GSK subsequently licensed worldwide commercial rights to Alfasigma S.p.A. on 22 April 2026, a deal that suggests Lynavoy was viewed as non-core to the post-rotation portfolio.
The pipeline economics also shifted with two acquisitions. The completed RAPT Therapeutics deal at US$2.3 billion brings ozureprubart, a long-acting anti-immunoglobulin E monoclonal antibody in phase IIb development for prophylactic protection against food allergens. The post-balance-sheet 35Pharma acquisition for US$950 million adds HS235, a potential best-in-class molecule for pulmonary hypertension targeting the activin receptor signalling pathway. Both deals expand GSK’s specialty footprint in disease areas with limited current treatment options and high pricing power, and both add R&D commitments rather than near-term revenue.
What does the ViiV Healthcare shareholding restructure with Shionogi and Pfizer mean for GSK’s HIV economics and capital allocation flexibility?
On 31 March 2026, GSK completed the ViiV Healthcare shareholding restructure under which Shionogi increased its economic interest from 10 per cent to 21.7 per cent through a new $2.125 billion investment, while Pfizer’s 11.7 per cent economic interest was cancelled and $1.875 billion was returned to Pfizer. GSK retained its 78.3 per cent economic interest, received a $250 million special dividend, and extinguished the Pfizer put option liability, which had stood at £822 million as at 31 December 2025.
The transaction matters for three reasons. First, it removes a contingent liability from the GSK balance sheet that had previously been remeasured each quarter and had introduced material volatility into Total operating profit. Second, it locks in Shionogi as a long-term capital partner in the HIV business at a moment when ViiV Healthcare is preparing for the dolutegravir loss of exclusivity transition and ramping investment in long-acting regimens. Third, the cash mechanics improved free cash flow in the quarter, with the $250 million special dividend a meaningful contributor to the £815 million free cash inflow versus £697 million in Q1 2025.
The Shionogi contingent consideration liability remains, however. As at 31 March 2026 the contingent consideration on the former Shionogi-ViiV Healthcare joint venture stood at £5.36 billion, with £1.24 billion expected to be paid within twelve months. Cash payments to Shionogi during the quarter totalled £362 million, and the remeasurement of the liability through the income statement contributed a £288 million charge as adjusting items, primarily reflecting exchange movements and discount unwind. This is the largest single source of difference between GSK Total and Core results, and it will continue to drag on Total operating profit as long as long-acting injectable performance remains strong, an unusual feature where commercial success creates accounting headwinds.
How is the GSK agreement with the United States government on Section 232 tariffs reshaping the commercial outlook through 2029?
On 9 April 2026, GSK, ViiV Healthcare and the United States government entered into a definitive agreement reflecting Section 232 tariff relief through 20 January 2029, subject to final implementation including participation in the United States government’s Generous Model programme. This followed the 2 April 2026 Section 232 proclamation by President Donald Trump imposing a 100 per cent tariff on patented pharmaceuticals and associated pharmaceutical ingredients beginning on 31 July 2026.
The agreement removes what would otherwise have been a material headwind to GSK United States turnover and gross margin. The United States accounts for £3.74 billion of group turnover in the quarter, or 49 per cent of total revenue, with Specialty Medicines growth of 16 per cent in the region driven by HIV, Oncology, Benlysta and Nucala. A 100 per cent tariff applied across this base would have either compressed gross margin substantially if absorbed, or compressed volume materially if passed through to payers, neither of which would have been compatible with the reaffirmed core operating profit guidance.
The structural takeaway is that GSK has successfully navigated the most consequential trade policy shift affecting global pharmaceuticals in decades, alongside ViiV Healthcare. The downside scenario is that the agreement is conditional on continued participation in the Generous Model programme, the parameters of which have not been disclosed and which may evolve under future administrations. GSK has bought three years of certainty, not permanence.
What do the Vaccines and General Medicines numbers tell senior pharmaceutical executives about competitive dynamics and pricing pressure?
The Vaccines segment grew 4 per cent at constant exchange rates to £2.15 billion, but the headline number obscures meaningful divergence beneath it. Shingrix delivered a record £1.03 billion at 20 per cent constant exchange rate growth, with Europe up 51 per cent driven by expanded public funding and private market demand, and the United States up 12 per cent on favourable channel inventory movements including the launch of a pre-filled syringe presentation. The cumulative immunisation rate in the United States reached 45 per cent, up 4 percentage points on twelve months earlier, indicating continued runway for Shingrix volume despite the strong base.
Outside Shingrix, the Vaccines portfolio is under pressure. Arexvy fell 18 per cent at constant exchange rates to £65 million on slow United States out-of-season uptake. Meningitis fell 3 per cent on timing of Menveo deliveries in International. Other Paediatric and Adult Vaccines fell 9 per cent on competitive pressure for Synflorix in emerging markets and lower demand for Hepatitis, Boostrix and Infanrix vaccines in the United States. The implication is that the Vaccines growth narrative is increasingly a Shingrix narrative, and the Arexvy commercial trajectory in adults aged 60 and over is no longer the high-conviction growth story it was projected to be at launch.
General Medicines fell 6 per cent at constant exchange rates to £2.25 billion. Trelegy delivered £646 million broadly stable performance, with strong Europe and International volume growth offset by United States declines from Medicare benefit design changes and channel mix pressures. The wider respiratory portfolio, including Relvar and Breo Ellipta, Seretide and Advair, and Ventolin, is in structural decline from generic erosion. Other General Medicines fell 12 per cent. The segment is now a managed-decline portfolio rather than a growth contributor, and the strategic question for GSK is how long it should continue to support these legacy assets versus accelerating divestment, as it did with the Rockville manufacturing facility sale to Samsung Biologics that contributed £375 million to other operating income in the quarter.
What does the GSK capital allocation framework signal to institutional investors about discipline and shareholder returns through 2026?
GSK declared a 17 pence first interim dividend for Q1 2026, up from 16 pence in Q1 2025, with the expected full-year 2026 dividend at 70 pence. The £2 billion share buyback programme announced at full-year 2024 results is now £1.7 billion executed, with the remaining £300 million expected to complete by the end of Q2 2026. Cash generated from operations was £1.35 billion and free cash inflow was £815 million, up 17 per cent on Q1 2025.
Net debt rose to £15.61 billion at 31 March 2026 from £14.45 billion at 31 December 2025, primarily reflecting the £1.40 billion net acquisition cost of RAPT Therapeutics, £643 million of dividends paid to shareholders, £326 million of share buyback activity, and a £154 million exchange loss on net debt. The increase is contained relative to operating cash generation, but the post-balance-sheet 35Pharma acquisition at US$950 million will add further leverage in Q2.
The capital allocation discipline test for GSK is whether the combination of dividend, buyback and tuck-in acquisitions can be sustained without a material increase in net debt to core operating profit. At current run-rates, that ratio remains comfortable, but the pipeline of small to mid-cap biopharma acquisitions, alongside the multi-billion-pound contingent consideration cash payments to Shionogi, will keep the balance sheet under continuous management for the next several years.
Key takeaways on what this development means for GSK, its competitors and the global biopharmaceutical industry
- GSK Specialty Medicines now contribute 42 per cent of group turnover and grew 14 per cent at constant exchange rates, validating the strategic rotation away from Vaccines and General Medicines as the primary growth drivers
- HIV long-acting injectables Apretude and Cabenuva drove 73 per cent of HIV growth, signalling that ViiV Healthcare is on track to manage the dolutegravir loss of exclusivity transition through portfolio shift rather than absolute decline
- Bepirovirsen filings in the US, EU, China and Japan position GSK to launch the first finite six-month chronic hepatitis B therapy from late 2026, opening a market segment with an estimated 250 million eligible patients globally
- The ViiV Healthcare shareholding restructure with Shionogi removes the Pfizer put option liability, locks in long-term capital partnership and adds a $250 million special dividend to free cash flow
- The Section 232 tariff relief agreement through 20 January 2029 protects 49 per cent of GSK turnover from the most consequential trade policy shift affecting global pharmaceuticals in decades
- Shingrix delivered a record £1.03 billion quarter, but masks structural weakness across Arexvy, Meningitis and Other Paediatric and Adult Vaccines, narrowing the Vaccines growth narrative to a single asset
- General Medicines is now a managed-decline portfolio falling 6 per cent at constant exchange rates, raising the question of further divestment after the Samsung Biologics Rockville manufacturing facility sale
- RAPT Therapeutics and 35Pharma acquisitions, combined with phase III readouts due in 2026 for camlipixant, depemokimab and Jemperli, define the next 18 months of GSK pipeline catalyst flow
- The £2 billion share buyback is 85 per cent complete, the dividend is on a 70 pence trajectory for 2026, and net debt at £15.61 billion remains contained relative to £2.65 billion of quarterly core operating profit
- Concentration risk is the central long-term concern, with fewer than ten Specialty Medicines assets carrying the bulk of growth, and any clinical or commercial setback in this group would compress the 2031 outlook of more than £40 billion in turnover
Discover more from Business-News-Today.com
Subscribe to get the latest posts sent to your email.
